Efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: a recent update

• Main Authors: Selvamani, Shanmugaprakasham, Mehta, Vijay, El Enshasy, Hesham Ali, Thevarajoo, Suganthi, El Adawi, Hala, Zeini, Ibrahim, Pham, Khoa, Varzakas, Theodoros, Abomoelak, Bassam
• Format: Article
• Language: English
• Published: Elsevier B.V. 2022
• Subjects: Q Science (General)
• Online Access: http://eprints.utm.my/103958/1/HeshamAli2022_EfficacyofProbioticsBasedInterventions.pdf; http://eprints.utm.my/103958/; http://dx.doi.org/10.1016/j.sjbs.2022.02.044

Probiotics such as Lactobacillus spp. play an important role in human health as they embark beneficial effect on the human gastrointestinal microflora composition and immune system. Dysbiosis in the gastrointestinal microbial composition has been identified as a major contributor to chronic inflammatory conditions, such as inflammatory bowel disease (IBD). Higher prevalence of IBD is often recorded in most of the developed Western countries, but recent data has shown an increase in previously regarded as lower risk regions, such as Japan, Malaysia, Singapore, and India. Although the IBD etiology remains a subject of speculation, the disease is likely to have developed because of interaction between extrinsic environmental elements; the host's immune system, and the gut microbial composition. Compared to conventional treatments, probiotics and probiotic-based interventions including the introduction of specific prebiotics, symbiotic and postbiotic products had been demonstrated as more promising therapeutic measures. The present review discusses the association between gut dysbiosis, the pathogenesis of IBD, and risk factors leading to gut dysbiosis. In addition, it discusses recent studies focused on the alteration of the gastrointestinal microbiome as an effective therapy for IBD. The impact of the COVID-19 pandemic and other viral infections on IBD are also discussed in this review. Clinical and animal-based studies have shown that probiotic-based therapies can restore the gastrointestinal microbiota balance and reduce gut inflammations. Therefore, this review also assesses the status quo of these microbial-based therapies for the treatment of IBD. A better understanding of the mechanisms of their actions on modulating altered gut microbiota is required to enhance the effectiveness of the IBD therapeutics.